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Abstract: Food intolerances are estimated to affect up to 20% of the population but
complete understanding of diagnosis and management is complicated, given presentation and
non-immunological mechanisms associated vary greatly. This review aims to provide a scientific
update on common food intolerances resulting in gastrointestinal and/or extra-intestinal symptoms.
FODMAP sensitivity has strong evidence supporting its mechanisms of increased osmotic activity and
fermentation with the resulting distention leading to symptoms in those with visceral hypersensitivity.
For many of the other food intolerances reviewed including non-coeliac gluten/wheat sensitivity, food
additives and bioactive food chemicals, the findings show that there is a shortage of reproducible
well-designed double-blind, placebo-controlled studies, making understanding of the mechanisms,
diagnosis and management difficult. Enzyme deficiencies have been proposed to result in other
food sensitivities including low amine oxidase activity resulting in histamine intolerance and
sucrase-isomaltase deficiency resulting in reduced tolerance to sugars and starch. Lack of reliable
diagnostic biomarkers for all food intolerances result in an inability to target specific foods in the
individual. As such, a trial-and-error approach is used, whereby suspected food constituents are
reduced for a short-period and then re-challenged to assess response. Future studies should aim to
identify biomarkers to predict response to dietary therapies.
Keywords: food intolerance; dietary therapy; food hypersensitivity; functional gastrointestinal
disorders
1. Introduction
Adverse food reactions are defined as any abnormal reaction following the ingestion of food. The
different adverse reactions are described as food hypersensitivity, including food intolerance and food
allergy, or food aversion, which is a psychological avoidance by Pavlovian conditioning of adverse
reactions [1]. There are key pathophysiological differences between food allergy and food intolerance,
resulting in different diagnostic strategies and therapeutic options and are divided according to having
an immune basis or not. The definition of food intolerance is a non-immunological response initiated
by a food or food component at a dose normally tolerated and account for most adverse food responses.
Food allergy is an abnormal immune response to a food protein mediated by immunoglobulin E
(IgE), non-IgE or mixed IgE/non-IgE immunological mechanisms. The prevalence of food allergy
varies affecting 1–2% of adults and less than 10% of children [2]. In contrast, food intolerance is
estimated to affect up to 20% of the population [3]. Despite food intolerance being so common
worldwide, the diagnosis is often not straightforward and requires an understanding of the varied
clinical presentation including severity and timing of symptom onset. This is further complicated by
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the various mechanisms of food intolerance that can exist, ranging from pharmacological (e.g. caffeine),
to enzyme deficiencies (e.g. lactose malabsorption), to non-specific gastrointestinal (GI) functioning [2].
The aim of this narrative review was to critically evaluate and synthesize the key evidence and
scientific understanding for the most common food intolerances. Each type of food intolerance assessed
presents an overview of the food component and where it is found, a description of the induced
response including any prevalence data, an overview of the mechanisms of how the food may induce
its response and suggested diagnosis and management. Recent literature was analyzed via search
databases including Medline, PubMed and Scopus to conduct this narrative review.
2. Sensitivities (Non-Allergic)
2.1. FODMAPs
Naturally occurring and present in a wide variety of foods are fermentable carbohydrates
termed ‘FODMAPs’ (denoting fermentable oligo- di- mono-saccharides and polyols). This group
of carbohydrates has been identified to trigger symptoms in patients with functional GI symptoms
such as in irritable bowel syndrome (IBS) [4]. The low FODMAP diet has been extensively studied
worldwide and shown good evidence for efficacy, is supported by meta-analyses [5,6] and has been
incorporated into clinical guidelines [7]. An important factor that has allowed for reproducible results
has been the establishment of food analysis techniques and subsequent detailed food composition data
available [8–13]. The low FODMAP diet reduces intake of carbohydrate subgroups including (i) excess
fructose present in foods such as honey, apples and mangoes, (ii) lactose present in milk and yoghurt
(in the presence of lactase deficiency), (iii) polyols (largely comprised of sorbitol and mannitol) present
in avocado and pears, iv) fructans present in wheat, onion and garlic, and (v) galacto-oligosaccharides
present in legumes and nuts. Detailed and regularly updated food lists are available elsewhere [14].
While a wide range of foods are classified as high in FODMAP content, no one food group is excluded
from the diet. Therefore, when the diet is properly implemented with suitable alternatives included,
nutritional adequacy is largely maintained [15].
2.1.1. FODMAP Induced Response
Consumption of a high FODMAP diet in sensitive individuals is thought to be associated with
lower GI symptoms of abdominal pain, bloating, flatulence, and altered bowel habits. Randomized
controlled trials using a low FODMAP diet have noted improvement in overall abdominal symptoms,
pain, bloating, and bowel habit [4,16–18]. However, one study found significance in reducing abdominal
pain, but not overall symptom control, although this may be an artifact of the study design [19]. Studies
have noted that a low FODMAP diet can improve both diarrhea and constipation [4], although less
data is available for the constipation predominant subtype. More recently, studies have suggested
that FODMAPs may alter upper GI motility, affecting intra-gastric pressure [20] and may be useful in
the management of functional dyspepsia [21]. Extra-intestinal symptoms have not been well studied
with the low FODMAP diet, although fatigue has also been noted to improve [22]. Improvement in
symptoms with the use of the low FODMAP diet in cohorts of IBS patients have been shown to vary
between 50–80% [23]. This range is likely to be influenced by several factors including study design,
patient selection and FODMAP intakes within habitual diets.
2.1.2. Proposed Mechanisms of FODMAP Induced Symptoms
Two main mechanisms of action were originally proposed for the effect of FODMAPs on symptom
induction. Firstly, short-chain poorly absorbed carbohydrates present in the small intestinal lumen
have an osmotic effect, increasing water delivery to the lumen. This mechanism has been confirmed
whereby increased eﬄuent output was shown in ileostomates given a high FODMAP diet [24],
as well as higher osmotic volume noted in MRI studies [25,26]. Secondly, the delivery of rapidly
fermentable carbohydrates to the colon leads to fermentation by colonic bacteria resulting in increased
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gas production. This mechanism has been confirmed via studies using MRI [25,26] and breath
testing [22]. The combined effects of increased water delivery and gas in the lumen cause distention
leading to pain and discomfort in patients with visceral hypersensitivity. These increased symptoms
in susceptible individuals have been shown in carefully designed studies with adequate subject
blinding [4,16]. It has also been shown that this effect is specific to those with visceral hypersensitivity,
with minimal symptoms noted in healthy controls [4,26]. More recently, other mechanisms of action
have been proposed such as potential of immune activation from high FODMAP foods due to significant
reductions in urinary histamine [27] and pro-inflammatory cytokines [28] following a low FODMAP
diet. However, further data is required to corroborate these findings and confirm their influence on
symptomatic response.
2.1.3. Diagnosis and Management of FODMAP Related Intolerances
The low FODMAP diet may be implemented following a diagnosis of IBS based on symptom
criteria (Rome IV criteria), with adequate exclusion of organic disease [29]. Prior to commencement, a
lactose breath test may be used to assess the need for lactose restriction. However, no other biomarkers
or testing can provide reliable information regarding food tolerance to the various FODMAP subgroups.
The low FODMAP diet should be implemented under guidance of a dietitian and is designed to be a
three-phase diet. This includes a short-term (2–8 week) reduction in FODMAP intake [30], followed
by strategic re-challenge to assess tolerance [31], and finally long-term maintenance where foods
are only avoided as identified during re-challenge to maintain symptom control [32]. The United
Kingdom National Institute for Health and Care Excellence (NICE) guidelines for adults with IBS
suggest that the low FODMAP diet can be used as a second-line therapy following general lifestyle and
dietary advice such as consumption of regular meals and avoidance of suspected trigger foods [33].
Certainly, the dietary advice should be tailored to the individual’s habitual diet and how their culture
and cuisine may affect their FODMAP intake, highlighting the individual role of the dietitian in the
implementation process.
As with any restrictive diet, the potential consequences of the dietary alterations during a low
FODMAP diet should be considered. Firstly, high FODMAP foods are generally good sources of
prebiotics, especially those containing oligosaccharides, and hence reduced intake may alter the
microbiota profile. Short-term studies have suggested a low FODMAP diet may result in reductions
in overall bacterial abundance, bifidobacteria and Faecalibacterium prausnitzii [34,35], although the
long-term consequences on the microbiota following re-challenge is not known. Secondly, alterations
in nutritional adequacy has been raised as a concern for patients utilizing the diet, with some studies
showing reductions in calcium [34] and fibre [36] intakes during the restrictive phase of the low
FODMAP diet and one study from the UK suggesting that those on the diet were less likely to meet the
national dietary guidelines [37]. As with alterations to the microbiota, little is known of the long-term
consequences of the diet on nutritional adequacy. One study with 6 month follow up showed that fibre
intakes returned to pre-intervention levels following re-challenge [17], suggesting that the long-term
consequences are likely to be minimal so long as re-challenge is undertaken. In addition to the need
for long-term data, future studies should assess the ability of patients to be compliant with the low
FODMAP diet. It is thought that dietitian guidance is key to the success of the diet [38], but further data
is needed to understand dietary compliance, nutritional adequacy and effects on the microbiota profile
both in the short- and long-term depending on mode of education (i.e., dietitian taught, physician
taught or self-implemented).
2.2. Wheat
The two parts of wheat relevant for discussion for food intolerance are the protein and carbohydrate
fractions. Gluten is the main storage protein of wheat grains and is a complex mixture of hundreds of
related but distinct proteins, mainly gliadin and glutenin. Similar storage proteins exist in rye, barley
and oats, and are collectively referred to as “gluten”. Gluten contributes to the dough quality and
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is predominantly found in sources such as pasta, cake, pastries and biscuits, but can also be used as
a binding and extending agent in processed foods. Other low molecular weight proteins found in
wheat and related cereals are called α-amylase/trypsin inhibitors (ATIs), however these contribute less
than 4% of the total protein content [39]. Another part of the protein component is wheat germ lectin
agglutinin known for their binding action to expressed sugars [40]. The carbohydrate component
(primarily fructan) of the wheat structure is discussed in the FODMAP section of this review.
2.2.1. Wheat Induced Response
Outside of the auto-immune condition of coeliac disease and wheat allergy (both of which will
not be discussed in this review), gluten is associated with GI symptoms including abdominal pain,
bloating and bowel habit abnormalities, so-called ‘non-coeliac gluten/wheat sensitivity’ (NCG/WS).
In addition to the GI response, there are various systemic manifestations reported to be associated
with wheat intake, including disorders of the neuropsychiatric area such as “foggy mind”, headache,
fatigue and dermatological and musculoskeletal symptoms (i.e., leg or arm numbness) [41,42]. Despite
frequent self-diagnosis of NCG/WS, reproducibility of these symptoms is limited following a process
of double-blind, placebo-controlled (DBPC) challenges [36,43], for example only 5% and 14% of two
cohorts of self-reported NCG/WS patients showed symptomatic response to gluten [36,44]. Other DBPC
trials using gluten powered challenges in IBS patients show conflicting results, showing symptom
induction with gluten, however caution is warranted when drawing comparisons given study design
differences (e.g., non-crossover) [45].
2.2.2. Proposed Mechanisms of Wheat Related Intolerances
Due to the lack of reproducibility in clinical response, the mechanisms by which gluten
causes symptoms within the food intolerance setting have been difficult to conclusively understand.
Mechanistic studies have hinted at various roles for gluten’s action including, but not limited to,
increased lipopolysaccharide-binding protein [46], increased eosinophils [47], both innate [48] and
adaptive [49] immune activation, increased intestinal permeability and gut microbiota changes [50].
The evidence for mechanisms of ATIs remains in its infancy. ATIs activate innate immune cells via
stimulation of toll-like receptor 4, which then induce the release of pro-inflammatory cytokines and
chemokines [51]. Some in vitro and in vivo work has suggested that these ATIs may increase the
gluten-specific T-cell response in coeliac disease [51]. It has been suggested that this inflammatory
response may exacerbate inflammation at extra intestinal sites [52]. Wheat lectin agglutinin has shown
in vitro that it can increase intestinal permeability by its epithelial damaging and immune effects [53].
The heterogeneity of results combined with consistent evidence indicative of the overlap between
IBS and gluten-related disorders and high placebo and nocebo responses [36], means elucidating the
underlying mechanisms of true wheat or gluten intolerance requires much more data.
2.2.3. Diagnosis and Management of Wheat Related Intolerances
Given there are no validated diagnostic biomarkers, the definition according to the scientific
literature for NCG/WS is where subjects are responsive to a gluten-free diet and react to re-challenge
with gluten compared to placebo [41]. This DBPC gluten re-challenge method is fundamentally
complex and time-consuming to undertake, however critical to identifying and further examining the
NCG/WS population. Care should be taken to ensure coeliac disease is definitively ruled out, especially
where latent or subclinical coeliac markers of anti-tissue transglutaminase exist or in subjects with the
coeliac associated genotype of HLA-DQ2/8. Clinical management, particularly for GI symptomatic
improvement is likely to come from implementing the low FODMAP diet [36]. Furthermore, because
of the coexistence of fructans and gluten in wheat, identifying the causative factor(s) is a crucial
step in confirming which of the gluten-free or low FODMAP diets to instruct. The first randomised
placebo-controlled trial to demonstrate that patients with NCGS appear to be intolerant to fructans not
gluten [54] strengthens the argument for FODMAP (especially fructan) restriction as a first step. More
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attention to extra-intestinal sensations and wellbeing, including anxiety and depression, might inform
why patients continue to follow a GFD and report to feel better.
2.3. Histamine
Histamine is a biogenic amine that is present in the body but also in many foods. It is found
in significant amounts in fermented and similar biogenic amines and can also be found in canned
food, ready meals, semi-finished products or products that have been stored for a long time. The
more perishable the food and the higher the protein content, the more important it is to consider
food preparation and storage [55]. Table 1 outlines food groups containing histamine that have been
reported to cause discomfort.
Table 1. Foods containing histamine [56].
Meat Sausages of any kind, salami, air-dried and corked meat, ham, etc.
Fish Dried or preserved fish, such as herring, tuna, mackerel, sardines and anchovies,seafood, fish sauces.
Cheese All types of hard, soft and processed cheese
Vegetables Eggplant, avocado, sauerkraut, spinach, tomatoes incl. tomato juice/ketchup
Drinks and liquids
Vinegar or alcohol of all kinds, mainly red wine, beers, champagne, whisky and
cognac; alcohol in general reduces degradation of histamine and increases the
permeability of the intestine and can therefore worsen the symptoms of histamine
intolerance in general
2.3.1. Histamine Induced Response
Histamine intolerance can lead to unspecific GI symptoms and extra-intestinal symptoms, which
occur mainly during and immediately following meals. Symptoms associated with histamine can
occur in isolation or in combination (Table 2) [57,58].
Table 2. Diagnosis of histamine intolerance.
Diagnostic criteria [58]
The diagnosis of histamine intolerance is made by a combination of the following criteria:
• presenting ≥2 typical symptoms of histamine intolerance (see below)
• improvement through histamine-free diet
• improvement through antihistaminergic medication.
Symptom types [57,58]
Skin Itching, sudden reddening of the skin (flush symptoms) on the face and/or body, veryrarely hives, angioedema (different to urticaria) and other exanthemas
Digestion Nausea, vomiting, diarrhea, abdominal pain
Circulation Tachycardia, drop in blood pressure, dizziness
Respiratory Chronic nasal flow, sneezing attacks
Neurological Headaches, migraines
Gynecological Menstrual cramps
2.3.2. Proposed Mechanisms of Histamine Intolerance
Histamine intolerance results from an imbalance of accumulated or ingested histamine and the
reduced ability to degrade histamine [59]. In healthy individuals, amine oxidases can quickly detoxify
histamine ingested with food, while people with low amine oxidase activity run the risk of histamine
toxicity. Diamine oxidase (DAO) is the main enzyme for the metabolism of ingested histamine. A
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second enzyme involved in the breakdown of histamine is histamine-N-methyltransferase (HNMT),
a cytosolic protein that can only convert histamine in the intracellular space of cells. A disturbed
or slowed histamine degradation due to reduced DAO activity and the resulting histamine excess
may cause the symptoms mentioned above, particularly in cases of high intakes of dietary histamine.
Genetic variants may also play a role [60].
Histamine occurs in different concentrations in animal and plant foods but is also produced and
denatured by the body itself, for example in the intestinal microbiome. Histamine produced in the
body seems to have less effect on histamine intolerance, except in situations such as mastocytosis [61]
with an increased number of mast cells or the so-called mast cell activation syndrome (MCAS), in which
spontaneous mast cell release due to still partially unknown factors leads to spontaneous histamine
release in the body [62].
2.3.3. Diagnosis and Management of Histamine Intolerance
Histamine intolerance remains an exclusion diagnosis, as there are no clear diagnostic criteria nor
biomarkers for histamine intolerance. The diagnosis of histamine intolerance is made by a combination
of criteria (Table 2) [58].
Other food intolerances, GI disease, IgE-mediated food allergies and underlying mastocytosis
should be excluded before a diagnosis can be made. If histamine intolerance is still suspected,
avoidance of histamine-rich foods for 4 to 6 weeks is undertaken. The measurement of DAO or
histamine levels in the blood has been scientifically inconclusive and is not recommended for routine
diagnosis or only after well-defined dietary regimens. A recent study has shown increased DAO after
histamine restriction, reflecting dietary compliance [63]. Some genetic tests involved in the two main
histamine degradation pathways, including DAO and HNMT are available on the market; however,
evidence-based studies on their relevance in histamine intolerance are still lacking. On the other
hand, the measurement of tryptase in serum can be helpful in obtaining evidence of the underlying
mastocytosis. If the diagnosis is still unclear after all these steps, a DBPC oral histamine provocation
may be the last evidential indication of diagnosis. Such an oral challenge requires a timely specific
protocol with supplementary dietary and psychosomatic support.
A low histamine diet is the first priority in management, which includes a three-stage diet change
as shown in Figure 1. As a supporting measure, the enzyme DAO can be taken orally approximately one
hour before histamine-rich food is consumed. In some cases, regular use of H1-blockers (antihistamines)
may also help relieve symptoms. Long-term restriction should be avoided and should only be followed
in close consultation with the doctor and/or nutritionist/dietitian. If no symptom improvement is
observed, all foods should be gradually reintroduced.
2.4. Food Additives and Bioactive Food Chemicals
Thousands of different food additives are used throughout the food industry for various functions,
especially to preserve food and improve taste or appearance. They are generally synthetic and natural
substances that cannot be consumed alone as food themselves. Food additives are classified based
on their function and property including preservatives, flavors, emulsifiers, thickeners, humectants,
firming agents and flavor enhancers. A small number of additives have been implicated in IgE-mediated
or other immunological or non-immunological adverse reactions.
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A low food chemical d et encompasses restriction of a wide range of bioactive food additives and
preservatives that occur naturally or are artificially added to foods (Table 3). The low food chemical
diet, also referred to as “The Elimination Diet“ was originally conceptualized by the Royal Prince
Alfred Hospital Allergy Unit in Sydney, Australia [64] and is thought to reduce GI symptoms, although
data from controlled trials is lacking. While some food composition data is available, the food chemical
content of foods is likely to be influenced by growing conditions, storage, food preparation, and
cooking methods [65]. For example, in one study of the salicylate content of foods, an unpeeled pink
lady apple had a salicylate content of 9.0 mg/kg, while a peeled pink lady apple had a content of
2.9 mg/kg [65]. This indicates that a significant portion of the salicylate content is located in the skin, an
important observation for clinical practice. Other factors are likely to alter the food chemical content,
such as length of time left in storage and cooking times.
Similar to ‘The Elimination Diet’ other diets low in food chemicals have been proposed and used
worldwide although they are poorly studied. For example, ‘The Feingold Diet’ originally designed in
the 1970’s to reduce attention deficit hyperactivity disorder (ADHD) in children eliminated artificial
sweeteners, colours and preservatives from the diet but one re-challenge study using food colouring was
unable to show an effect [66]. The ‘Few Foods diet’ excludes all foods except five or six (e.g. lamb, potato,
rice, one of the brassicas, pear and tap water) but was shown to be ineffective at reducing refractory
atopic dermatitis in children in one study [67]. Clearly more studies are needed to evaluate the use of
such diets, both on their efficacy at reducing symptoms (gastrointestinal and extra-intestinal) as well as
their feasibility and ability to maintain nutritional adequacy during implementation. Unfortunately
the lack of studies assessing different diets low in food chemical content have likely been impeded
by challenges in designing adequately controlled placebo-controlled studies, difficulty in obtaining
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funding to undertake expensive placebo-controlled feeding studies, and challenges in ethical issues
related to risks of re-challenge studies in patients who could have potential fatal reactions such as
those in steroid dependent asthma. With a surge in research and community interest in the role of diet
for treatment of disease, funding may become easier to access and promote further dietary research
within this area.
Table 3. Examples of foods containing natural and added food chemicals thought to induce
gastrointestinal and extra-intestinal symptoms in gastrointestinal conditions.
FOOD CHEMICAL FOOD SOURCES [64,65]
Natural food chemicals
Amines Cheese, chocolate, banana, ham, fish
Glutamate Tomato
Salicylates Apples, tomatoes
Added food chemicals
Antioxidants Oils, margarine
Benzoates Soft drinks, cordials
Colors Confectionary, jelly
Monosodium glutamate (MSG) Chinese take-away, packaged foods
Nitrates Deli meats
Propionates Breads
Sorbic acid Processed cheese slices
Sulfites Soft drink, cordials, dried fruit
2.4.1. Food Additives and Chemical Induced Response
Prevalence of self-reported symptoms to food additives has been reported to be 0.01–0.23% in
adults [68], and challenge studies have found 2–7% prevalence in atopic children [69]. The limited
evidence comes mostly from case studies or small poorly controlled challenge studies, conducted in
patients with asthma or chronic idiopathic urticaria/angioedema [70]. Food additives and chemicals are
thought to contribute to both GI symptoms similar to IBS, as well as extra-intestinal symptoms including
urticaria, headache, eczema, rhinitis, nasal congestion, or post nasal drip [71]. No controlled dietary
trials have been published using the low chemical diet in its entirety in patients with GI disorders
and limited data exists for other symptom responses. Small studies have investigated the effect of
singular food chemicals. One small study of patients with a dual diagnosis of fibromyalgia and IBS,
showed that a 4-week dietary exclusion of glutamate reduced >30% of symptoms in 84% of the patients,
and symptoms were evoked by 3-day re-challenge [72]. The prevalence of GI symptoms following
consumption of higher doses of salicylates from aspirin and other non-steroidal anti-inflammatory
drugs has been suggested to be between 10-20% in those with asthma, and 0.6-2.5% in the general
population [73]. However, it is unknown how this translates to the relatively lower doses found
through dietary sources alone. It is also unknown if hypersensitivity to one food chemical predisposes
an individual to be sensitive to other food chemical types.
2.4.2. Proposed Mechanisms of Food Additives and Chemicals
Due to the lack of controlled studies, mechanisms of action of food additives in symptom
provocation are poorly understood. It is likely that studies of each individual food additive will be
required to elucidate their specific pathophysiology, few studies have been conducted to date with some
suggestions of potential mechanisms of individual food additives. Inconsistent reports of adverse effects
exist for tartrazine (food dye) [74], sulphites [75], benzoic acid [76] and monosodium glutamate [77]
limiting reproducible evidence for mechanistic understanding. For most of these additives, several
mechanisms have been proposed including IgE-mediated reactions and mitochondrial enzyme
deficiencies. Specific mechanisms have been proposed to cause asthmatic reactions to sulphites with
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mode of exposure likely to be an important factor with inhalation of sulfur dioxide and the warm acidic
environment of the mouth possibly triggering respiratory symptoms. Additionally, it has been proposed
that the parasympathetic system may be involved whereby inadequate sulphite oxidase results in
accumulation of sulphite, causing cholinergic mediated bronchoconstriction [78]. More recently,
evidence from rat model studies has shown two commonly used emulsifiers, carboxymethylcellulose
and polysorbate-80, can induce low grade inflammation and obesity/metabolic syndrome in wild-type
hosts and may impair the epithelial barrier [79,80]. Similarly, nanoparticles such as titanium dioxide,
a substance added to foods as a whitening agent, has been shown to alter nutrient absorption and
disrupt the epithelial barrier impairing gut homeostasis in pre-clinical models at relevant exposure
doses [45,81,82]. It has been proposed that food chemicals may induce a non-specific antigen-induced
pseudo-allergic hypersensitivity [64,83]. Clearly more data is required to elucidate specific mechanisms
of action of sensitivities to specific food additives.
2.4.3. Diagnosis and Management of Food Additive and Chemical Sensitivity
There are no diagnostic tests available to assess food additive or chemical sensitivity. Despite
the lack of efficacy data, the low chemical diet is used in clinical practice [71]. Like other exclusion
diets, the low chemical diet is used as an initial short-term (2–6 week) restriction followed by strategic
re-challenge to assess tolerance to each food chemical. Each food chemical is typically re-challenged
in gradually increasing doses over a 3-day period [73]. Some chemicals such as dietary salicylates
require challenging over longer periods (i.e., up to 10 days), due to the potential for a gradual
build-up over several days that may be required to elicit a symptom response. Due to the number
of food chemicals, the re-challenge process can be lengthy and result in extended use of the low
chemical diet [71]. Concerns have been raised regarding the restrictive nature of the diet and potential
negative consequences for nutritional adequacy, especially when used in pediatric patients [84], and
as such it is key that a patient is supervised by a dietitian during the initial restriction as well as the
re-challenge phases.
3. Genetic
3.1. Sucrose and Starch (Sucrase-Isomaltase Deficiency)
During normal carbohydrate digestion, sucrase cleaves the 1-4 linked glucose oligomers of sucrose
and maltose, while isomaltase cleaves branched (1-6 linked) α-limit dextrins. Following this enzymatic
digestion, the monosaccharides are absorbed across the epithelial barrier [85]. When there is an absence
or reduction in sucrase and isomaltase, dietary carbohydrates such as sucrose and starches may result
in symptom induction due to the inability or reduced ability for absorption.
3.1.1. Sucrase-Isomaltase Deficiency Response
In sucrase-isomaltase deficiency, sucrose and starches present in the lumen act as FODMAPs
resulting in symptoms of diarrhea, bloating and abdominal pain, with symptom severity dependent
on residual sucrase and isomaltase activity [85].
3.1.2. Proposed Mechanisms of Sucrase-Isomaltase Deficiency
Sucrase-isomaltase deficiency may occur either due to genetic variants, or as a secondary or
acquired event. There have been more than 25 genetic variants identified in the human sucrase gene.
Variants can occur on the sucrase or isomaltase subunits, and as such varied degrees of symptom
severity occur [85]. Secondary sucrase-isomaltase deficiency is usually transient and can be reversed
with treatment of the primary condition. For example, studies in pigs have shown that villous atrophy
such as that seen in coeliac disease, may result in sucrase-isomaltase deficiency. It has been estimated
that 2–9% of those of North American or European decent may be affected by genetic variants, but the
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prevalence of secondary deficiency is not known [85]. A Swedish study of 250 patients found those
with genetic sucrase-isomaltase variants were predisposed to IBS [86].
Regardless of the cause of sucrase-isomaltase deficiency, the absence or deficiency in enzyme
activity results in undigested sugars in the lumen which then act as FODMAPs. The presence of
undigested sugars in the lumen has osmotic effects resulting in hyperosmolar diarrhea, and subsequent
fermentation in the colon results in gas production [85]. The distention leading from the increased
water delivery and gas production in the lumen results in symptoms genesis.
3.1.3. Diagnosis and Management of Sucrase-Isomaltase Deficiency
The gold standard for diagnosis is duodenal or jejunal biopsies, although studies to date have
largely been conducted in children [85]. Inaccuracies in diagnosis are likely due to the complexities in
sample collection and storage that are required for analysis of sucrase, lactase, isomaltase and maltase
activity [87]. Due to the invasive nature of obtaining biopsies, alternative methods have been suggested
include sucrose breath testing, genetic sequencing which should be considered in combination with
the clinical picture, or use of dietary restriction followed by oral enzyme replacement trials [85,87].
Dietary treatment may include restriction of sugars and starch, followed by gradual re-introduction
to determine tolerance, although compliance rates are poor and efficacy of dietary modification have
not been well studied [87]. An alternative or adjunct therapy would be the use of enzyme replacement
therapy with sacrosidase, which has shown good effect in small studies [87,88].
4. Discussion
4.1. Recommendations for Future Research
Double-blind placebo-controlled with cross-over trials are the current gold standard for confirming
the dietary factor(s) involved in symptom generation and are therefore required to confirm any food
intolerance discussed in the current review. Greater methodological difficulties exist in the design and
implementation of clinical dietary trials compared to pharmacological trials. For example, lack of
isolation of food components e.g. co-existence of gluten and fructan within the same foods, difficulty
in design of placebo diets, and challenges in blinding of participants. Hence, the same criteria for
trial methodology used in pharmacological studies may not be appropriate [89]. In order to ensure
well designed dietary trials can be conducted, adequate food compositional data is required. Food
compositional data is currently available for a range of foods containing gluten, wheat and FODMAPs.
However, further food compositional data is required for other potential problematic food components
such as histamine and food chemicals.
Once food compositional data is available and clear efficacy has been established, further research
should investigate the following key factors. Firstly, assess the role of mode of education on symptomatic
response i.e., does the efficacy vary depending on how the information is delivered, either via physician,
dietitian, nurse, or online and app-based mediums. Secondly, what is the level of dietary restriction
required to achieve symptom resolution. For example, a strict gluten-free diet is required in coeliac
disease to ensure mucosal healing, but it is unknown if this same level of restriction be necessary for
those with NCG/WS to reduce symptoms. Likewise, feeding studies assessing efficacy of the low
FODMAP diet reduced intake to 3 g/day [4], compared to dietary education trials achieving 10–12 g/day
with similar levels of efficacy achieved [16,17]. Finally, assessment of the long-term outcomes and
safety implications are required. As many efficacy trials will end after an initial restriction period, little
is known about the long-term dietary requirements, effect on nutritional profiles and quality of life, as
well as effect on microbiota and metabolomic profiles.
The ability to predict response to dietary therapies would significantly enhance treatment
strategies which has been reviewed previously [90]. Prediction of response would allow clinicians to
tailor which therapy is used, and avoid potential negative implications of dietary restrictions such
as reduced nutritional adequacy and alterations to the microbiome. Unfortunately non-invasive
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techniques such as hydrogen breath testing for carbohydrate intolerances lack reproducibility and
are not recommended [91]. Hence, recent studies have investigated alternative strategies to predict
response such as faecal profiling of microbiota [92,93] and volatile organic compounds [94] or urinary
metabolomics [27]. However, despite increased research interest, ability to predict response is still in
its infancy and is far from implementation into practice.
The ability to identify ways to predict response to dietary therapies may also lead to improved
mechanistic understanding of functional GI conditions and allow for creation of ways to improve
tolerance to foods. For example, certain microbiota or metabolomics profiles may indicate that
supplementation with a certain pre- pro- or syn-biotic is required, shifting the profile to one in which
symptom response to a certain food component is mitigated.
4.2. Implications and Recommendations for Clinical Practice
Due to the lack of tests available to identify intolerance to specific food components, a trial-and-error
approach is used in clinical practice. This approach utilizes strategic short-term removal of food
components followed by re-introduction to assess symptom response. Selection of which food
components to trial removing may be based on the clinical picture including symptomatic profile,
habitual diet, patients suspicions of food intolerances, and where applicable, genetic variations.
Appropriate implementation and education about avoidance of food triggers is required across
any food intolerance (and allergy). Patients attempting to modify their diet benefit from guidance
by a dietitian, likely due to improved understanding and compliance, resulting in greater symptom
response [30,32,95]. The role of the dietitian is important not only during the initial stages of establishing
the dietary modification whereby the dietitian can modify the level of restriction required based on
the clinical picture; but is also integral in the implementation and interpretation of re-challenges to
assess tolerance to specific food triggers [31]. Appropriate education also ensures patients do not
over-restrict their diet unnecessarily or undertake ‘diet-stacking’ in which they accumulate multiple
dietary restrictions resulting in worsened food variety and nutritional adequacy.
In some cases, combination therapies may allow for more personalized and targeted therapies.
For example, in a re-analysis of patients within a trial assessing the low FODMAP diet, patients who
were carriers of the sucrase-isomaltase hypomorphic variants were less likely to respond to a 4-week
low FODMAP diet trial [96]. In these patients, sucrose and starch restriction alone or in combination
with a low FODMAP diet may have been more efficacious. Likewise, implementation of simultaneous
probiotic supplementation may mitigate any potential negative consequences of the low FODMAP
diet on the microbiota [16]. Additionally, strategies to improve tolerance to specific food components
may reduce the level of dietary restriction necessary such as the use of α-galactosidase in patients who
do not tolerate galacto-oligosaccharides [97].
5. Conclusions
It is clear that while there are a large number of suspected food components inducing symptoms,
there is a notable shortage of well-designed studies making understanding of the reaction, diagnosis
and management difficult. Future studies should use carefully planned double-blind studies with
defined inclusion criteria to reduce the knowledge gaps and elucidate clear mechanisms of action of
food intolerances.
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